The New Biochemical Background A number of drugs which share an ability to inhibit the enzyme monoamine oxidase (EC 1.4.3.4 ) differ widely in structure (Pletscher et al. 1966 ). Whilst they provide, in general, a highly effective form of treatment for depression, certain representatives of the group are considerably more successful in this role than others (Davis 1965) . This puzzling inhomogeneity has led some authors to question whether their therapeutic ability derives from their action on monoamine oxidase at all (Hendley & Snyder 1968 ). However, a series of observations from the author's laboratory over the past five years (for review, see Sandler & Youdim 1972) now seem likely to resolve this problem. The insoluble enzyme, which is located on the outer membrane of the mitochondrion, has been shown to exist as a mixture of multiple forms, each with its own different substrate and inhibitor specificities, pHactivity and heat inactivation characteristics. The number of these forms, as separated electrophoretically, varies from tissue to tissue; thus, four are present in rat (Youdim et al. 1969 ) and human (Collins, Sandler, Williams & Youdim 1970) brain, five in liver (Collins et al. 1968 ) and one only in platelets (Collins & Sandler 1971 ). In the human brain at least, the specific activities of each of the constituent forms of the enzyme for different substrates varies spectacularly from area to area (Collins, Sandler, Williams & Youdim 1970 ). One of these electrophoretic bands of activity, which we have termed MAORI is present in most tissues; it has many physicochemical characteristics pointing to an existence as a completely separate enzyme (Youdim 1972) . In particular, it possesses a high degree of preference for dopamine as substrate. It is of interest that its highest specific activity towards this amine has been found in the basal ganglia where dopamine is in most plentiful supply. It also seems likely that hormonally dependent variations in activity, manifested in particular by human (Southgate et al. 1968 ) and rat (Collins, Pryse-Davies, Sandler & Southgate 1970) endometrium, derive from a special characteristic of the dopamine specific band .
There is some evidence, at present indirect, pointing to the existence of these multiple forms in vivo as well as in vitro . Certain slight differences in in vivo compared with in vitro sensitivity to inhibitors may perhaps be explained in terms of compartmental barriers and metabolism of the inhibitor concerned to active metabolites. If the multiple forms are not just a preparation artifactand the evidence to the contrary, although strong, is by no means absolutetheir existence might well explain why some inhibitors are more effective than others, because of their differential inhibition of one form more than another. Such a hypothesis brings in its train the concept of a beneficial accumulation of a particular amine substrate at a specific brain site following dosage with those inhibitors active in depression: conversely, inhibitors which do not confer therapeutical benefit will spare this site. To pinpoint where these drugs act in depression, and identify the crucial amine or amines which build up in consequence, it would be necessary to map brain monoamine oxidase according to the substrate and inhibitor characteristics of its individual forms at different brain locations, a daunting task. The number of potential substrates is large; some of them in addition are technically difficult to assay with purified enzyme preparations. Nevertheless, our eventual hope is that specific inhibitors, aimed at particular multiple forms, will prove a more effective weapon against depression than presentday blunderbuss therapy. A precedent for an inhibitor with such a specific action already exists in the drug clorgyline, which has a proportionally greater inhibitory effect on some forms of the enzyme compared with others (Johnston 1968 ). It might even, in the process, be possible to synthesize an inhibitor which spares the tyramineoxidizing ability of the enzyme. Tyraminecontaining foods are potentially dangerous for patients being treated with monoamine oxidase inhibitors (Marley & Blackwell 1970) .
It is a common experience, in this connexion, that some patients seem to ingest tyramine with impunity during drug therapy; others undergo a severe adverse reaction which may even, on occasion, be fatal. A possible solution to this puzzle has been provided by studies on patients with tyramine-sensitive migraine (Youdim et al. 1971) . Although the greater proportion of ingested tyramine is inactivated by oxidative deamination with monoamine oxidase, a varying amount, some 10% in normal subjects, is degraded by sulphate conjugation. When monoamine oxidase is inhibited, it seems possible that the conjugation mechanism acts as a 'safety valve', allowing the individual to dispose, when the need arises, of an otherwise toxic accumulation of ingested free amine. During the migraine study referred to above, a significant deficit in tyramineconjugating ability was noted in one group of affected subjects. It seems possible that patients falling into this category (whether they suffer from migraine or not) would be specially at risk if they were ever to undergo inhibitor treatment. To test this hypothesis, a group of patients who had suffered adverse reactions to cheese and other tyramine-containing dietary constituents whilst being treated with these drugs were given an oral tyramine load. None was on inhibitor therapy at the time of the test. A highly significant decrease in their ability to conjugate tyramine was observed compared with normal controls (Sandler, Bonham Carter, Pare & Cuthbert 1973, in preparation) . If this enzyme deficit can be confirmed and shown to be not merely a characteristic of depressive illness and also, if the drug itself can be shown to have no long-term inhibitory effect on the conjugating mechanism (cf. Hargreaves 1968), then it will obviously be necessary in future to screen candidates for monoamine oxidase inhibitor therapy by preliminary oral tyramine challenge to ascertain wlhether their conjugating ability is sufficient for safety. In this study the response of depressed patients to phenelzine was compared with their response to placebo, and the relationship between acetylator status and effectiveness of this drug w,as examined.
Introduction: The metabolism of some substances including sulphadimidine and hydrazine derivatives is determined by a genetic polymorphism which controls acetylation. Any population can be divided into fast and slow acetylators (Evans et al. 1960O, Evans & White 1964 . Phenelzine is a hydrazine derivative and therefore should be a substrate for polymorphic acetylation. Simple sulphadimidine loading techniques for determining acetylator status have lately been introduced (Evans 1969) and it seemed that the use of these might offer a means of predicting response to phenelzine.
Procedure and method: We studied outpatients whose illness was biased towards the neurotic rather than the endogenous form: 257 consecutive referrals with a complaint of depression were seen. By means of the Standardized Psychiatric Interview devised by Goldberg et al. (1970) and the neurotic/endogenous rating of Carney et al. (1965) we selected 97 patients with a depressive illness of neurotic type not secondary to physical or psychiatric disease who agreed to enter the study. A side-effects check list (Table 1) was administered at the time of the first contact. Before treatment was begun the acetylator phenotypes of the patients were determined by the method described by Price Evans, although the results of this estimation were not known to the investigators until the study was complete. The patients were randomly and blindly allocated to two groups, one being given phenelzine 15 mg three times a day and the other an identical 'Based on a paper published in the Lancet (Johnstone & Marsh 1973 ) and printed by kind permission of the Editor of that journal
